Chris Schott
Stock Analyst at JP Morgan
(4.15)
# 461
Out of 5,147 analysts
154
Total ratings
64.49%
Success rate
9.36%
Average return
Main Sectors:
Stocks Rated by Chris Schott
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ELAN Elanco Animal Health | Maintains: Overweight | $24 → $28 | $26.40 | +6.06% | 5 | Feb 19, 2026 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $1,150 → $1,300 | $1,051.99 | +23.58% | 24 | Feb 5, 2026 | |
| REGN Regeneron Pharmaceuticals | Maintains: Overweight | $850 → $950 | $781.67 | +21.53% | 9 | Feb 2, 2026 | |
| TEVA Teva Pharmaceutical Industries | Maintains: Overweight | $28 → $35 | $33.86 | +3.37% | 20 | Dec 16, 2025 | |
| PRGO Perrigo Company | Maintains: Neutral | $20 → $18 | $13.22 | +36.16% | 14 | Dec 15, 2025 | |
| OGN Organon & Co. | Maintains: Underweight | $14 → $12 | $7.29 | +64.61% | 3 | Nov 11, 2025 | |
| ZTS Zoetis | Maintains: Overweight | $230 → $200 | $131.10 | +52.56% | 3 | Nov 5, 2025 | |
| IDXX IDEXX Laboratories | Maintains: Overweight | $675 → $775 | $656.73 | +18.01% | 9 | Nov 4, 2025 | |
| ABBV AbbVie | Maintains: Overweight | $250 → $260 | $232.08 | +12.03% | 4 | Nov 3, 2025 | |
| GILD Gilead Sciences | Maintains: Overweight | $145 → $150 | $148.95 | +0.70% | 8 | Oct 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $14 | $13.81 | +1.38% | 3 | Sep 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $185 → $175 | $191.82 | -8.77% | 4 | May 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $45 → $42 | $46.21 | -9.11% | 4 | Feb 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $270 | $388.16 | -30.44% | 1 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $36 → $34 | $27.65 | +22.97% | 10 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $120 → $125 | $123.82 | +0.95% | 7 | Feb 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $14 | $14.93 | -6.23% | 2 | Nov 15, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $11 | $1.67 | +558.68% | 4 | Nov 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $5.93 | - | 4 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $78 | $62.37 | +25.06% | 7 | Oct 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $700 → $950 | $0.38 | +249,900.00% | 4 | May 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.26 | - | 2 | May 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $45 → $50 | $21.91 | +128.21% | 3 | Nov 2, 2018 |
Elanco Animal Health
Feb 19, 2026
Maintains: Overweight
Price Target: $24 → $28
Current: $26.40
Upside: +6.06%
Eli Lilly and Company
Feb 5, 2026
Maintains: Overweight
Price Target: $1,150 → $1,300
Current: $1,051.99
Upside: +23.58%
Regeneron Pharmaceuticals
Feb 2, 2026
Maintains: Overweight
Price Target: $850 → $950
Current: $781.67
Upside: +21.53%
Teva Pharmaceutical Industries
Dec 16, 2025
Maintains: Overweight
Price Target: $28 → $35
Current: $33.86
Upside: +3.37%
Perrigo Company
Dec 15, 2025
Maintains: Neutral
Price Target: $20 → $18
Current: $13.22
Upside: +36.16%
Organon & Co.
Nov 11, 2025
Maintains: Underweight
Price Target: $14 → $12
Current: $7.29
Upside: +64.61%
Zoetis
Nov 5, 2025
Maintains: Overweight
Price Target: $230 → $200
Current: $131.10
Upside: +52.56%
IDEXX Laboratories
Nov 4, 2025
Maintains: Overweight
Price Target: $675 → $775
Current: $656.73
Upside: +18.01%
AbbVie
Nov 3, 2025
Maintains: Overweight
Price Target: $250 → $260
Current: $232.08
Upside: +12.03%
Gilead Sciences
Oct 31, 2025
Maintains: Overweight
Price Target: $145 → $150
Current: $148.95
Upside: +0.70%
Sep 16, 2025
Maintains: Overweight
Price Target: $12 → $14
Current: $13.81
Upside: +1.38%
May 5, 2025
Maintains: Neutral
Price Target: $185 → $175
Current: $191.82
Upside: -8.77%
Feb 20, 2024
Maintains: Overweight
Price Target: $45 → $42
Current: $46.21
Upside: -9.11%
Oct 20, 2023
Reinstates: Neutral
Price Target: $270
Current: $388.16
Upside: -30.44%
Oct 16, 2023
Maintains: Neutral
Price Target: $36 → $34
Current: $27.65
Upside: +22.97%
Feb 23, 2023
Maintains: Overweight
Price Target: $120 → $125
Current: $123.82
Upside: +0.95%
Nov 15, 2022
Maintains: Neutral
Price Target: $13 → $14
Current: $14.93
Upside: -6.23%
Nov 14, 2022
Maintains: Neutral
Price Target: $13 → $11
Current: $1.67
Upside: +558.68%
Jul 29, 2022
Downgrades: Neutral
Price Target: n/a
Current: $5.93
Upside: -
Oct 16, 2020
Maintains: Overweight
Price Target: $74 → $78
Current: $62.37
Upside: +25.06%
May 27, 2020
Maintains: Overweight
Price Target: $700 → $950
Current: $0.38
Upside: +249,900.00%
May 19, 2020
Downgrades: Neutral
Price Target: n/a
Current: $2.26
Upside: -
Nov 2, 2018
Maintains: Neutral
Price Target: $45 → $50
Current: $21.91
Upside: +128.21%